New Mexico

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. Because New Mexico requires a synchronous visit to establish the provider-patient relationship, a New Mexico-licensed clinician completes that review with a brief scheduled video visit right after your intake. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any New Mexico address in 2–3 business days.

The process is the same as for semaglutide — complete Pallas's online intake, and a New Mexico-licensed clinician completes a brief scheduled video visit to establish care before prescribing. If appropriate, your clinician can prescribe either compounded tirzepatide, prepared per-patient by a US-licensed §503A pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is legal and available to eligible New Mexico residents through licensed telehealth. It is prepared per-patient by US-licensed 503A and 503B compounding pharmacies under FDCA §503A, and a New Mexico-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves New Mexico with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes, within their scope of practice. New Mexico-licensed prescribers — physicians and, within their scope of practice, nurse practitioners and physician assistants — can prescribe semaglutide and tirzepatide via telehealth once New Mexico's video-visit requirement is met. Every Pallas clinician who treats New Mexico patients holds an active New Mexico license appropriate to their role.

Several licensed telehealth platforms serve New Mexico residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are licensed in New Mexico, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves New Mexico residents.

New Mexico Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid rules do not apply to our prescriptions.

Yes — New Mexico requires one live video visit with a New Mexico-licensed provider to establish the provider-patient relationship before a GLP-1 can be prescribed. Pallas schedules that video visit right after your online intake, and it is typically brief. Once your relationship is established, ongoing care — check-ins, messaging, and refills — continues asynchronously, without another scheduled call unless your history calls for it.

Most New Mexico patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Albuquerque, Las Cruces, Santa Fe, and other New Mexico metros typically ship fastest; rural addresses may take an extra day.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your New Mexico address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Albuquerque, Las Cruces, or a rural New Mexico ZIP code.

Eligibility is always decided by a New Mexico-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your New Mexico-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your New Mexico-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the New Mexico Medical Board then meets you for a short scheduled video visit — required by New Mexico rules to establish care — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any New Mexico address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team from the Pallas app or your patient portal, and change your plan or cancel anytime from the portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any New Mexico address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any New Mexico address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® (pen or pill), Zepbound^® and Foundayo^™ for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to New Mexico patients cash-pay: the daily Wegovy^® pill and Foundayo^™ are $299 for your first month, then $499 every 4 weeks, and the weekly pens start at $1,069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in New Mexico during intake.

Coverage of GLP-1 medications for weight loss through Turquoise Care is limited. New Mexico Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Turquoise Care or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in New Mexico, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1,069/mo. Two: if a clinician licensed in New Mexico determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in New Mexico weighs your history, goals, and budget to recommend a starting point.

It depends on what you are comparing. Pallas is a cash-pay telehealth service that serves every ZIP code in New Mexico with one all-in plan price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. There is no separate membership fee, and nothing is charged until a clinician prescribes. New Mexico requires one live video visit, which is included. Before paying any service, check whether the quoted price includes the medication or is a membership billed on top of it, whether the company is LegitScript-certified, and whether you are charged before a clinician has prescribed.